# Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

**Authors:** Ana Peixoto, Luís Cirnes, Ana Luísa Carvalho, Maria João Andrade, Maria José Brito, Paula Borralho, Nuno Coimbra, Pedro M. Borralho, Ana Sofia Carneiro, Lisandra Castro, Lurdes Correia, Maria Rita Dionísio, Carlos Faria, Paulo Figueiredo, Ana Gomes, Joana Paixão, Manuela Pinheiro, Hugo Prazeres, Joana Ribeiro, Natália Salgueiro, Fernando. C Schmitt, Fátima Silva, Ana Rita Silvestre, Ana Carla Sousa, Joana Almeida-Tavares, Manuel R. Teixeira, Saudade André, Jose Carlos Machado

PMC · DOI: 10.3389/fmolb.2024.1298522 · Frontiers in Molecular Biosciences · 2024-04-24

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}
- **Diseases:** breast cancer (MESH:D001943)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11077270/full.md

---
Source: https://tomesphere.com/paper/PMC11077270